Longitudinal study comparing IgG antibodies induced by heterologous primeboost COVID19 vaccine
J Med Virol
; 95(1): 28379, Jan. 2023. graf, tab
Article
en En
| CONASS, SES-SP, SESSP-IDPCPROD, SES-SP
| ID: biblio-1418125
Biblioteca responsable:
BR79.1
ABSTRACT
ABSTRACT Vaccines are critical costeffective tools to control the COVID19 pandemic. The heterologous primeboost vaccination has been used by many countries to overcome supply issues, so the effectiveness and safety of this strategy need to be better clarified. This study aims to verify the effect of heterologous primeboost COVID19 vaccination on healthcare professionals from Dante Pazzanese Hospital in Brazil. It was performed serological assays of vaccinated individuals after 2dose of CoronaVac (Sinovac; n = 89) or ChAdOx1 nCoV19 (OxfordAstraZeneca; n = 166) followed by a BNT162b2 booster (PfizerBioNTech; n = 255). The serum antibodies antiS (spike), antiN (nucleocapsid), and antiRBD (receptor binding domain) were assessed by enzymelinked immunosorbent assay. The heterologous booster dose induced a 10fold higher antiSpike antibody regardless of the 2dose of a prime vaccine. It was strikingly observed that BNT162b2 enhanced levels of antispike antibodies, even in those individuals who did not previously respond to the 2dose of CoronaVac. In conclusion, the heterologous scheme of vaccination using mRNA as a booster vaccine efficiently enhanced the antibody response against SARSCoV2, especially benefiting those elderly who were seronegative with a virusinactivated vaccine.
Texto completo:
1
Colección:
06-national
/
BR
Base de datos:
CONASS
/
SES-SP
/
SESSP-IDPCPROD
Asunto principal:
Inmunoglobulina G
/
Nucleocápside
/
Glicoproteína de la Espiga del Coronavirus
/
SARS-CoV-2
Tipo de estudio:
Observational_studies
Límite:
Humans
Idioma:
En
Revista:
J Med Virol
Año:
2023
Tipo del documento:
Article